Denmark, Novo Nordisk

Novo Nordisk invests $1.2bn in new Denmark facility
Construction has already begun on the Ozempic-producer’s new Danish production facility and 40,000m² warehouse.
Novo Nordisk invests $1.2 bln in new rare disease drugs plant in Denmark
Danish drugmaker Novo Nordisk will invest 8.5 billion crowns ($1.20 billion) in a new facility in Odense, Denmark, for the production of rare disease drugs, it said on Monday.
Novo Nordisk Invests $1.2 Billion in New Factory in Denmark
Ozempic maker Novo Nordisk A/S is investing 8.5 billion kroner ($1.2 billion) to build a new major factory in Denmark to help meet growing demand for its blockbuster drugs.
Novo Nordisk to build $1.2B rare disease drug factory in Denmark
Shortly after unveiling a $400 million upgrade at its campus in Hillerød, Denmark, Novo Nordisk is reinforcing its commitment to the country by breaking ground on the first new production facility | Novo Nordisk is laying out 8.
Novo Nordisk to invest $1.2 billion in new plant in Denmark
Danish drugmaker Novo Nordisk will invest 8.5 billion crowns ($1.20 billion) in a new facility in Odense, Denmark, for the production of rare disease drugs, it said on Monday. The company said in a statement the site will include a warehouse as well as a factory.
Novo Nordisk invests $1.2B to build new factory in Denmark
Danish pharmaceutical giant Novo Nordisk, maker of diabetes and weight-loss treatments Ozempic and Wegovy, which have gained popularity in recent
Novo Nordisk to Invest $1.2 Billion in New Production Facility in Denmark
The pharmaceutical company will establish a production facility in Odense to accommodate multiple product types within the rare disease area, such as haemophilia.
Novo Nordisk To Invest DKK 8.5 Bln For New Production Facility In Denmark
Healthcare company Novo Nordisk A/S (NVO) announced Monday that it plans to invest 8.5 billion Danish kroner to establish a
Novo Nordisk Invests DKK8.5 Bln in New Production Facility in Odense, Denmark
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing opportunities, strengthen advisor-client relationships and build investor experiences. Learn More. Back To Top
Weight-loss Drugmaker Novo Nordisk Invests $1.2 Bn In New Factory In Denmark
Danish pharmaceutical giant Novo Nordisk, maker of diabetes and weight-loss treatments Ozempic and Wegovy, said Monday it was investing 8.5 billion kroner ($1.2 billion) to build a new factory in Denmark to produce drugs against rare diseases.
Novo Nordisk’s Hiring Binge Leaves Danish Firms Starved of Labor
The maker of weight-loss and diabetes drugs has supercharged the Danish economy — but other businesses complain that’s left ...
Novo Nordisk's Options Frenzy: What You Need to Know
Investors with a lot of money to spend have taken a bullish stance on Novo Nordisk NVO. And retail traders should know. We ...
Did Eli Lilly Just Say "Checkmate" to Novo Nordisk?
Eli Lilly (LLY -1.28%) and Novo Nordisk (NVO 1.03%) have competed for decades. They're both leaders in the areas of insulin ...
Novo Nordisk's CagriSema May Trump Lilly's Zepbound - Buy This Dip
NVO's CagriSema target of up to 25% in long-term weight loss is highly promising vs. 15% through Wegovy and 20% through ...
Novo Nordisk's Ozempic set to include kidney treatment label in EU
Novo Nordisk announced on Thursday that a key European Medicines Agency committee has backed a label update for weight-loss ...
FiercePharma1d
Novo Holdings set to close $16.5B Catalent buy in 'coming days' after deal clears antitrust hurdles
After clearing all regulatory hurdles associated with its proposed buyout of CDMO Catalent, Novo Holdings is nearly ready to ...
Novo Nordisk says Catalent buyout to close soon as regulatory conditions met
Novo Nordisk's (NVO) acquisition of three Catalent (CTLT) production sites to close soon as its parent wins regulatory nod ...
malaymail4h
Novo’s Ozempic under spotlight: Danish studies link diabetes drug to rare eye disease
Danish health authorities said on Monday they would ask the European Union’s drug regulator to review the findings of two ...